Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
ORLADEYO 150MG CAP is a federal award for 260-Network Contract Office 20 (36C260) held by Biocryst Pharmaceuticals, Inc. Estimated value $151K ($151K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: EARTH CITY MO.
Recompete timing
PublicCurrent PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26026F0294?
36C26026F0294 (Orladeyo 150mg CAP) is a 260-Network Contract Office 20 (36C260) award with a potential value of $151K, currently held by Biocryst Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C260-26-F-0294?
36C260-26-F-0294 is the dashed form of PIID 36C26026F0294 (Orladeyo 150mg CAP), held by Biocryst Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26026F0294?
260-Network Contract Office 20 (36C260) awarded 36C26026F0294 to Biocryst Pharmaceuticals, Inc (potential $151K).
Who is the incumbent on 36C26026F0294?
Biocryst Pharmaceuticals, Inc is the incumbent. The current period of performance ends Sep 30, 2026.
When does Biocryst Pharmaceuticals, Inc’s 36C26026F0294 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.